Mutation screening of patients with Alzheimer disease identifies APP locus duplication in a Swedish patient

Genetics Unit, Dept of Geriatric Medicine, Karolinska University Hospital, Huddinge, Sweden. .
BMC Research Notes 11/2011; 4(1):476. DOI: 10.1186/1756-0500-4-476
Source: PubMed


Missense mutations in three different genes encoding amyloid-β precursor protein, presenilin 1 and presenilin 2 are recognized to cause familial early-onset Alzheimer disease. Also duplications of the amyloid precursor protein gene have been shown to cause the disease. At the Dept. of Geriatric Medicine, Karolinska University Hospital, Sweden, patients are referred for mutation screening for the identification of nucleotide variations and for determining copy-number of the APP locus.
We combined the method of microsatellite marker genotyping with a quantitative real-time PCR analysis to detect duplications in patients with Alzheimer disease.
In 22 DNA samples from individuals diagnosed with clinical Alzheimer disease, we identified one patient carrying a duplication on chromosome 21 which included the APP locus. Further mapping of the chromosomal region by array-comparative genome hybridization showed that the duplication spanned a maximal region of 1.09 Mb.
This is the first report of an APP duplication in a Swedish Alzheimer patient and describes the use of quantitative real-time PCR as a tool for determining copy-number of the APP locus.

Download full-text


Available from: Caroline Graff,
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Alzheimer's disease (AD) is a neurodegenerative disorder characterized by neuritic plaques (main constituent: β-amyloid [Aβ]) and neurofibrillary tangles (hyperphosphorylated tau protein) in the brain. Abnormalities in Aβ and tau can be measured upon neuropathological examination, in cerebrospinal fluid or by PET. Etiologically, a growing body of evidence suggests that susceptibility to AD is genetically controlled. However, the precise nature of the underlying risk genes and their relation to AD biomarkers remains largely elusive. To this end, we performed a qualitative review of 17 studies (covering 47 polymorphisms in 26 genes) and investigated the potential relation between the most compelling AD risk genes and markers for Aβ and tau in cerebrospinal fluid, PET imaging and neuropathological examination. Of all covered genes, only APOE and PICALM showed consistent effects on Aβ but not on tau, while no obvious effects were observed for CLU, CR1, ACE, SORL and MAPT.
    Biomarkers in Medicine 08/2012; 6(4):477-95. DOI:10.2217/bmm.12.56 · 2.65 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Alzheimer's disease (AD) is the most common type of dementia in the elderly and has multiple causes. The amyloid precursor protein (APP), presenilin1 (PSEN1), and presenilin2 (PSEN2) genes were identified as causative genes in a small number of families with autosomal dominant early-onset forms of AD (ADEOAD). However, many AD cases are sporadic and the late-onset type, which develops after 65 years of age. The apolipoprotein gene (APOE) is the strongest risk gene for sporadic and familial late-onset AD (LOAD) regardless of ethnicity. Since about half of the patients with LOAD do not have the risk allele (ε4) of APOE and λs (=5) is larger than λsAPOE (=2.5), risk genes other than APOE are expected to be involved in LOAD. Based on the common disease-common variants hypothesis, genome-wide association studies (GWAS) were performed tenaciously to identify genes related to AD. However, even large-scale GWAS with relatively high frequency of single nucleotide polymorphisms did not reveal any additional risk genes with nearly equal power of APOE. Recently, individual whole genome or whole exon sequencing data obtained using next-generation sequencers have become available. Mutations in the causative genes of ADEOAD have been also observed in both familial LOAD and sporadic EOAD. Furthermore, new causative genes have been identifies in some families by whole genome or exome analyses. Considering the new common disease-rare variants hypothesis, personal genome sequence analysis is a potential strategy for identifying AD risk or protective genes.
    Brain and nerve = Shinkei kenkyū no shinpo 03/2013; 65(3):235-46.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Alzheimer's disease (AD) is the most common progressive neurodegenerative disease and the most common form of dementia in the elderly. It is a complex disorder with environmental and genetic components. There are two major types of AD, early onset and the more common late onset. The genetics of early-onset AD are largely understood with mutations in three different genes leading to the disease. In contrast, while susceptibility loci and alleles associated with late-onset AD have been identified using genetic association studies, the genetics of late-onset Alzheimer's disease are not fully understood. Here we review the known genetics of early- and late-onset AD, the clinical features of EOAD according to genotypes, and the clinical implications of the genetics of AD.
    BioMed Research International 05/2014; 2014(4):291862. DOI:10.1155/2014/291862 · 1.58 Impact Factor
Show more